Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Functionality of Albumin in the Context of Hemodialysis

Effects of Dialyzer Characteristics and Dialysis Mode on Functional Properties of Albumin in Patients With Chronic Hemodialysis Treatment

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. At the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chronically increased level of inflammation and usually incomplete removal of uraemic toxins. Both of these are closely linked with the functional properties of albumin. The aim of this study is to investigate the effects of various parameters of dialysis, in particular dialyzer properties and dialysis mode on the functional properties of albumin and to what extent these parameters can be used therapeutically, to improve the treatment quality of hemodialysis treatment in the long term by modifying albumin functional properties. Our own preliminary work in this field and the current state of research indicate that, for example, the use of high-flux dialyzers can contribute to a reduction of the oxidative stress level. It also appears possible that treatment mode (haemodiafiltration instead of haemodialysis) may also have an effect on the binding and detoxification efficiency of albumin and thus on the removal of uraemic toxins. Previous results have mostly been collected in observational studies. As a proof-of-concept study, this study will further investigate the concrete therapeutic applicability in an interventional study design.

Who May Be Eligible (Plain English)

Who May Qualify: - 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen Who Should NOT Join This Trial: - Age ≤ 18 years - Less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week - Acute or chronic liver disease (Child stage A or higher or fulfillment of the of the Kings College criteria) - Infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion - Acute or severe chronic infections - Acute tumor disease Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen Exclusion Criteria: * Age ≤ 18 years * Less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week * Acute or chronic liver disease (Child stage A or higher or fulfillment of the of the Kings College criteria) * Infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion * Acute or severe chronic infections * Acute tumor disease

Treatments Being Tested

OTHER

Hemodialysis mode, dialyzer type

Change of hemodialysis mode and dialyzer type

Locations (1)

University Hospital Essen
Essen, Germany